Table I.

Baseline clinical characteristics for patients in the chemotherapy-bevacizumab group vs. chemotherapy alone group prior and subsequent to propensity score matching.

A, Unmatched dataset
Characteristics	Chemotherapy-bevacizumab (n=43)	Chemotherapy alone (n=122)	P-value
Age, years			0.844
Median (range)	52 (37–72)	56 (27–76)
≤60	32	88
>60	11	34
Sex, n			0.287
Male	19	67
Female	24	55
Smoking history, n			0.583
Current/previous	14	47
Never	29	75
Histology, n			0.800
Adenocarcinoma	38	105
Squamous cell/adenosquamous carcinoma	5	17
EGFR mutation status			0.716
Mutant typea	17	44
Wild-type/unknown	26	78
Number of prior regimensb, n			0.009
Median (range)	3 (2–5)	2 (2–5)
≤3	28	103
>3	15	19
Chemotherapy regimen, n			<0.0001
Gemcitabine	30	39
Pemetrexed	5	31
Paclitaxel	3	8
Docetaxel	5	44
B, Matched (1:1) dataset
Characteristics	Chemotherapy-bevacizumab (n=38)	Chemotherapy alone (n=38)	P-value
Age, years			1.000
Median (range)	52 (40–71)	49 (38–76)
≤60	30	31
>60	8
Sex			0.492
Male	17	21
Female	21	17
Smoking history, n			0.240
Current/previous	26	20
Never	12	18
Histology, n			1.000
Adenocarcinoma	34	35
Squamous cell/	4	3
adenosquamous carcinoma
EGFR mutation status			0.641
Mutant typea	17	14
Wild-type/unknown	21	24
Number of prior regimensb, n			1.000
Median (range)	3 (2–5)	3 (2–4)
≤3	28	28
>3	10	10
Chemotherapy regimen, n			1.000
Gemcitabine	25	25
Pemetrexed	5	5
Paclitaxel	3	3
Docetaxel	5	5

EGFR, epidermal growth factor receptor.

^aMutant type included the exon 19 deletion and exon 21 L858R mutations.

^bPrior regimens included chemotherapy, EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors.